PALI - Why Is Gastrointestinal-Focused Palisade Bio Stock Trading Higher Today? | Benzinga
Palisade Bio Inc (NASDAQ: PALI) shares are trading higher after the company announced a licensing agreement with Giiant Pharma Inc.
The license provides the company with the exclusive worldwide rights to develop, manufacture, and commercialize Giiant's proprietary targeted prodrug platform focused on therapies for the multi-billion dollar irritatable bowel syndrome (IBD) market.
The licensed technologies include Giiant's precision delivery technology platform and multiple product ...